{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T03:45:48Z","timestamp":1793936748203,"version":"4.8.0"},"reference-count":28,"publisher":"American Society for Microbiology","issue":"8","license":[{"start":{"date-parts":[[2005,8,1]],"date-time":"2005-08-01T00:00:00Z","timestamp":1122854400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2005,8]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>Micafungin (FK463) is a new parenteral echinocandin. A multicenter, phase I, open-label, sequential-group dose escalation study was conducted to assess the safety, tolerability, and pharmacokinetics of micafungin in neutropenic pediatric patients. A total of 77 patients stratified by age (2 to 12 and 13 to 17 years) received micafungin. Therapy was initiated at 0.5 mg\/kg per day and escalated to higher dose levels of 1.0, 1.5, 2.0, 3.0, and 4.0 mg\/kg per day. Micafungin was administered within 24 h of initiating broad-spectrum antibacterial antibiotics for the new onset of fever and neutropenia. The most common overall adverse events in the study population were diarrhea (19.5%), epistaxis (18.2%), abdominal pain (16.9%), and headache (16.9%). Nine patients (12%) experienced adverse events considered by the investigator to be possibly related to the study drug. The most common related events were diarrhea, vomiting, and headache, all occurring in two patients each. There was no evidence of a dose-limiting toxicity as defined within the prespecified criteria of this clinical protocol. There was one death during the study due to septic shock. The pharmacokinetic profiles for micafungin over the 0.5- to 4.0-mg\/kg dose range demonstrated dose linearity. Clearance, volume of distribution, and half-life remained relatively constant over the dose range and did not change with repeated administration. The overall plasma pharmacokinetic profile was similar to that observed in adults. However, there was an inverse relation between age and clearance. For patients 2 to 8 years old, clearance was approximately 1.35 times that of patients \u22659 years of age. In summary, micafungin over a dosage range between 0.5 and 4.0 mg\/kg\/day in 77 febrile neutropenic pediatric patients displayed linear pharmacokinetics and increased clearance as a function of decreasing age.<\/jats:p>","DOI":"10.1128\/aac.49.8.3317-3324.2005","type":"journal-article","created":{"date-parts":[[2005,7,27]],"date-time":"2005-07-27T10:52:45Z","timestamp":1122461565000},"page":"3317-3324","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":205,"title":["Safety, Tolerability, and Pharmacokinetics of Micafungin (FK463) in Febrile Neutropenic Pediatric Patients"],"prefix":"10.1128","volume":"49","author":[{"given":"Nita L.","family":"Seibel","sequence":"first","affiliation":[{"name":"Children's National Medical Center, George Washington University School of Medicine, Washington, D.C. 20010"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cindy","family":"Schwartz","sequence":"additional","affiliation":[{"name":"Johns Hopkins Hospital, Baltimore, Maryland 21287"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Arrieta","sequence":"additional","affiliation":[{"name":"Children's Hospital of Orange County, Orange, California 92868-3874"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Flynn","sequence":"additional","affiliation":[{"name":"St. Jude Children's Hospital, Memphis, Tennessee 38105"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aziza","family":"Shad","sequence":"additional","affiliation":[{"name":"Georgetown University Hospital, Washington, D.C. 20007"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edith","family":"Albano","sequence":"additional","affiliation":[{"name":"University of Colorado Children's Hospital, Denver, Colorado 80218"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Keirns","sequence":"additional","affiliation":[{"name":"Fujisawa Healthcare, Inc., Deerfield, Illinois 60015-2548"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendi M.","family":"Lau","sequence":"additional","affiliation":[{"name":"Fujisawa Healthcare, Inc., Deerfield, Illinois 60015-2548"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David P.","family":"Facklam","sequence":"additional","affiliation":[{"name":"Fujisawa Healthcare, Inc., Deerfield, Illinois 60015-2548"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald N.","family":"Buell","sequence":"additional","affiliation":[{"name":"Fujisawa Healthcare, Inc., Deerfield, Illinois 60015-2548"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas J.","family":"Walsh","sequence":"additional","affiliation":[{"name":"National Cancer Institute, Bethesda, Maryland 20892-8322"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1086\/313445"},{"key":"e_1_3_2_3_2","first-page":"S15","volume":"18","year":"1996","unstructured":"Chanock, S. J., and T. J. Walsh. 1996. Evolving concepts of prevention and treatment of invasive fungal infections in pediatric bone marrow transplant recipients. Bone Marrow Transpl.18(Suppl. 3):S15-S20.","journal-title":"Bone Marrow Transpl."},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)14472-8"},{"key":"e_1_3_2_5_2","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1002\/cncr.10833","volume":"95","year":"2002","unstructured":"Gatta, G., R. Capocaccia, M. P. Coleman, L. A. G. Ries, and F. Berrino. 2002. Childhood cancer survival in Europe and the United States. Cancer95:1767-1772.","journal-title":"Cancer"},{"key":"e_1_3_2_6_2","first-page":"409","year":"1982","unstructured":"Gibaldi, M., and D. Perrier. 1982. Pharmacokinetics, 2nd ed., p. 409-416. Marcel Dekker, Inc., New York, N.Y.","journal-title":"Pharmacokinetics"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1439-0507.1999.00496.x"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.45.12.3322-3327.2001"},{"key":"e_1_3_2_9_2","first-page":"405","volume":"2","year":"2000","unstructured":"Groll, A. H., and T. J. Walsh. 2000. Evaluation of the antifungal echinocandin FK463. Curr. Opin. Investig. Drugs2:405-412.","journal-title":"Curr. Opin. Investig. Drugs"},{"key":"e_1_3_2_10_2","first-page":"417","year":"2003","unstructured":"Groll, A. H., and T. J. Walsh. 2003. Fungal infections in pediatric patients, p. 417-422. In M. McGinnis, M. Pfaller, and E. Anaissie (ed.), Clinical mycology. Churchill Livingstone, Philadelphia, Pa.","journal-title":"Clinical mycology"},{"key":"e_1_3_2_11_2","first-page":"3075","year":"2003","unstructured":"Groll, A., and T. J. Walsh. 2003. Antifungal agents, p. 3075-3108. In R. D. Feigin, J. D. Cherry, G. J. Demmler, and S. L. Kaplan (ed.), Textbook of pediatric infectious diseases.","journal-title":"Textbook of pediatric infectious diseases"},{"key":"e_1_3_2_12_2","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1002\/(SICI)1096-911X(199804)30:4<233::AID-MPO5>3.0.CO;2-H","volume":"30","year":"1998","unstructured":"Harris, R. E., H. N. Sather, and S. A. Feig. 1998. High-dose cytosine arabinoside and L-asparaginase in refractory acute lymphoblastic leukemia: the Children's Cancer Group experience. Med. Pediatr. Oncol.30:233.","journal-title":"Med. Pediatr. Oncol."},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.7164\/antibiotics.55.219"},{"key":"e_1_3_2_14_2","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1080\/10428190310001625719","volume":"45","year":"2004","unstructured":"Hayes-Lattin, B., and R. T. Maziarz. 2004. Update in the epidemiology, prophylaxis, and treatment of fungal infections in patients with hematologic disorders. Leuk. Lymphoma45:669-680.","journal-title":"Leuk. Lymphoma"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1702654"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.3.614-618.2000"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(05)81975-4"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.3.619-621.2000"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/46.3.485"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.6.1857-1869.2002"},{"key":"e_1_3_2_21_2","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1111\/j.1365-2036.2004.02083.x","volume":"20","year":"2004","unstructured":"Pettengell, K., J. Mynhardt, T. Kluyts, W. Lau, D. Facklam, and D. Buell. 2004. Successful treatment of oesophageal candidiasis by micafungin: a novel systemic antifungal agent. Aliment. Pharmacol. Ther.20:475-481.","journal-title":"Aliment. Pharmacol. Ther."},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.1.57-62.2000"},{"key":"e_1_3_2_23_2","unstructured":"Tukey J. W. 1977. Exploratory data analysis p. 43-45. Addison-Wesley Reading Mass."},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1086\/422312"},{"key":"e_1_3_2_25_2","unstructured":"Antimicrob. Agents Chemother."},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.6.2166-2172.2004"},{"key":"e_1_3_2_27_2","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1200\/JCO.1990.8.2.280","volume":"8","year":"1990","unstructured":"Wiley, J. M., N. Smith, B. G. Leventhal, M. L. Graham, L. C. Strauss, C. A. Hurwitz, J. Modlin, D. Mellits, R. Baumgardner, and B. J. Corden. 1990. Invasive fungal disease in pediatric acute leukemia patients with fever and neutropenia during induction chemotherapy: a multivariate analysis of risk factors. J. Clin. Oncol.8:280-286.","journal-title":"J. Clin. Oncol."},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(87)90949-1"},{"key":"e_1_3_2_29_2","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.1002\/cncr.11316","volume":"97","year":"2003","unstructured":"Xie, Y., S. M. Davies, Y. Xiang, L. L. Robison, and J. A. Ross. 2003. Trends in leukemia incidence and survival in the United States (1973-1998). Cancer97:2229-2235.","journal-title":"Cancer"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.49.8.3317-3324.2005","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.49.8.3317-3324.2005","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T18:51:05Z","timestamp":1645469465000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.49.8.3317-3324.2005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,8]]},"references-count":28,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2005,8]]}},"alternative-id":["10.1128\/AAC.49.8.3317-3324.2005"],"URL":"https:\/\/doi.org\/10.1128\/aac.49.8.3317-3324.2005","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,8]]},"assertion":[{"value":"2004-09-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2005-04-21","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2005-08-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}